Objectives: Monocyte/HDL-C is a marker of inflammation. One of the most common sites of metastasis by breast cancer is bone. This study was purposed to define the predictability of bone metastasis with the Monocyte/HDL-Cratio in breast cancer patients. Methods: Study consisted of patients diagnosed with breast cancer. Patients with breast cancer bone metastasis detected by whole body bone scan and pet-CT were included. Results: A comparison of monocyte/high-density lipoprotein was planned in patients with and without breast cancer bone metastases. Patients with hematological disease, using lipid-lowering drugs, and lipid metabolism disorders were excluded from the study. A statistically significant difference was determined between the patients' bone metastasis status and LDL values at 99% confidence level [t(207) = 1.899; p=0.049; p<0.05]. On the other hand, whether the patients have bone metastasis or not, no statistically significant difference was found in case of Monocyte/HDL (p = 0.878; p>0.05), Monocyte/Lymphocyte (p=0.239; p>0.05), HDL (p=0.235; p>0) 0.05), TG (p=0.819; p>0.05), and total cholesterol (p=0.285; p>0.05). Conclusion: This study was applied to determine the predictability of bone metastasis with the monocyte/HDL-C ratio in breast cancer patient. Monocyte/HDL of the patients having breast cancer bone metastasis (BCBM) was compared with non-BCBM patients but there was no significant correlation between monocyte/HDL-C, monocyte/lymphocyte, HDL-C, TG, and total cholesterol. Keywords: Bone Metastasis, Breast cancer, HDL-C, LDL- C
Corresponding Author: Fuzuli Tugrul